Smallpox Clinical Trial
Official title:
Clinical Protocol to Treat Individuals With Tecovirimat (ST-246) After Exposure to Orthopox Viruses
The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses.
Rationale: Tecovirimat (TPOXX) is approved by FDA for treatment of smallpox. However, the therapeutic human dose for treatment of orthopox virus infections or a significant adverse reaction to vaccinia resulting from vaccination, secondary transmission, or other exposure, has not yet been fully established. Treatment: Based on the interpretation of currently available animal efficacy and human safety and PK data, the proposed human adult or pediatric patient (≥ 40 kg) therapeutic regimen is 600 mg (3 capsules of 200 mg) orally twice daily (BID) for at least 14 days, taken 30 minutes after a meal consisting of about 600 calories and 30% (25 grams) fat, which is the same as treatment for smallpox. If a dose is missed it should be taken as soon as possible unless it is near the next dose time. Doses should not be doubled in the event of a missed dose. Treatment may be extended beyond 14 days, with sponsor approval, if the investigator deems necessary. Nonclinical safety data support use for up to 90 days. The pediatric dosing recommendation is derived from the TPOXX package insert based on the body weight: 200 mg twice daily for patients of 13-25kg (29-45pounds); 400 mg twice daily for patients 25-40kg (55-87pounds) and 600 mg twice daily for pediatric patients over 40kg (88pounds) Clinical Evaluation: Medical history and concomitant medications will be recorded, and a physical examination with vital signs [eg, body weight, blood pressure, heart rate, respiratory rate, temperature, and height (only once)] will be completed. Photographs of affected areas, should lesions develop, may be taken. Patients will be followed for at least 30 days after receiving the last tecovirimat dose or until their infection improves. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05976100 -
Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years
|
Phase 1 | |
| Completed |
NCT01540929 -
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
|
||
| Completed |
NCT00258947 -
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
|
Phase 2 | |
| Completed |
NCT00189969 -
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
|
Phase 1 | |
| Terminated |
NCT00053508 -
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
|
Phase 2 | |
| Completed |
NCT01317238 -
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
|
Phase 3 | |
| Completed |
NCT01056770 -
Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers
|
Phase 3 | |
| Completed |
NCT00998543 -
A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)
|
Phase 2 | |
| Withdrawn |
NCT00389103 -
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
|
Phase 1 | |
| Terminated |
NCT00282581 -
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
|
Phase 1 | |
| Completed |
NCT00133575 -
ACAM 3000 MVA at Harvard Medical School
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00103584 -
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
|
Phase 1/Phase 2 | |
| Completed |
NCT00050505 -
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
|
Phase 2 | |
| Completed |
NCT05846243 -
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
|
Phase 2/Phase 3 | |
| Completed |
NCT05935917 -
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00082446 -
Combination Study With MVA BN and Dryvax
|
Phase 1 | |
| Completed |
NCT00038987 -
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
|
Phase 1/Phase 2 | |
| Completed |
NCT05762523 -
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
|
Phase 1 | |
| Completed |
NCT04971109 -
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day
|
Phase 3 | |
| Completed |
NCT00646152 -
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
|
Phase 1 |